Tiziana shares are trading higher after the company announced FDA IND clearance of intranasal foralumab to be studied in Alzheimer's disease.
Portfolio Pulse from Benzinga Newsdesk
Tiziana Life Sciences announced that the FDA has cleared its Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease. This news has led to an increase in the company's share price.
August 15, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tiziana Life Sciences' shares are trading higher following the FDA's clearance of its IND application for intranasal foralumab for Alzheimer's disease study.
The FDA's clearance of Tiziana's IND application for intranasal foralumab for Alzheimer's disease study is a significant regulatory milestone for the company. This positive news has led to an increase in the company's share price, indicating a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100